List of Excipients in Branded Drug OLMESARTAN MEDOXOMIL AMLODIPINE AND HYDROCHLOROTHIAZIDE

Generic Drugs Containing OLMESARTAN MEDOXOMIL AMLODIPINE AND HYDROCHLOROTHIAZIDE

Company	Ingredient	NDC	Excipient
Macleods Pharmaceuticals Limited	olmesartan medoxomil amlodipine and hydrochlorothiazide	33342-243	CELLULOSE, MICROCRYSTALLINE
Macleods Pharmaceuticals Limited	olmesartan medoxomil amlodipine and hydrochlorothiazide	33342-243	CROSCARMELLOSE SODIUM
Macleods Pharmaceuticals Limited	olmesartan medoxomil amlodipine and hydrochlorothiazide	33342-243	FERRIC OXIDE RED
Macleods Pharmaceuticals Limited	olmesartan medoxomil amlodipine and hydrochlorothiazide	33342-243	FERRIC OXIDE YELLOW
Macleods Pharmaceuticals Limited	olmesartan medoxomil amlodipine and hydrochlorothiazide	33342-243	FERROSOFERRIC OXIDE

What are the Most Frequently-Used Excipients in OLMESARTAN MEDOXOMIL AMLODIPINE AND HYDROCHLOROTHIAZIDE?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	FERRIC OXIDE RED
1	FERRIC OXIDE YELLOW
1	FERROSOFERRIC OXIDE

Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide: Excipient Strategy and Commercial Opportunities

Last updated: August 6, 2026

The olmesartan medoxomil, amlodipine and hydrochlorothiazide combination is a mature fixed-dose antihypertensive platform with limited remaining originator exclusivity but continuing generic, private-label and international opportunities. The principal formulation challenge is combining a poorly soluble prodrug, a salt-form calcium-channel blocker and a diuretic in one tablet while maintaining dose uniformity, dissolution, stability and manufacturability.

The reference product is Tribenzor, marketed by Daiichi Sankyo, and approved by the FDA as an oral tablet containing olmesartan medoxomil, amlodipine and hydrochlorothiazide. The product is a small-molecule drug and is subject to the ANDA pathway, not the biosimilar pathway. Its commercial value is now driven primarily by manufacturing efficiency, portfolio breadth, regulatory execution and geographic expansion rather than by originator exclusivity.

What is the composition and regulatory status of olmesartan, amlodipine and hydrochlorothiazide?

Tribenzor combines three established antihypertensive agents:

Component	Pharmacologic class	Formulation role
Olmesartan medoxomil	Angiotensin II receptor blocker	Low-dose, poorly water-soluble prodrug
Amlodipine, generally supplied as amlodipine besylate	Dihydropyridine calcium-channel blocker	Low-dose active with high clinical potency
Hydrochlorothiazide	Thiazide diuretic	Diuretic component available at 12.5 mg or 25 mg

The FDA-approved product has multiple strength combinations based on 20 mg or 40 mg of olmesartan medoxomil, 5 mg or 10 mg of amlodipine, and 12.5 mg or 25 mg of hydrochlorothiazide. The combination is indicated for patients whose blood pressure is not adequately controlled with dual therapy or with separately titrated components. FDA approval was granted under NDA 202895 in 2010. [1]

The product has no biologic component. Biosimilar competition is therefore irrelevant. Competitive entry occurs through generic ANDAs, authorized generics, branded-generic products and country-specific multisource registrations.

What excipients are most suitable for this three-drug tablet?

A commercially robust formulation normally requires a direct-compression or dry-granulation excipient system that manages low-dose uniformity, poor solubility, lubrication sensitivity and chemical stability.

Recommended excipient architecture

Formulation function	Candidate excipients	Commercial rationale
Primary filler and compressibility	Microcrystalline cellulose, lactose monohydrate, mannitol, dibasic calcium phosphate	Provides tablet mass and acceptable compactibility
Disintegration	Crospovidone, croscarmellose sodium, sodium starch glycolate	Supports rapid breakup despite a multi-component matrix
Binder	Copovidone, povidone, low-substituted hydroxypropyl cellulose	Improves granule strength and content uniformity
Glidant	Colloidal silicon dioxide	Improves powder flow and die filling
Lubricant	Magnesium stearate, sodium stearyl fumarate	Controls ejection force and sticking
Wetting or dissolution aid	Poloxamer, sodium lauryl sulfate, surfactant-compatible polymer	Can improve wetting of olmesartan medoxomil
Film coating	Hypromellose, polyvinyl alcohol, polyethylene glycol, titanium dioxide, iron oxides	Provides identification, protection and swallowability

The formulation should not rely on a single high level of magnesium stearate. Excessive lubrication can reduce tablet tensile strength and slow dissolution, particularly for poorly soluble olmesartan medoxomil. Lubricant concentration and blending time should be treated as critical process variables.

A practical generic platform would use microcrystalline cellulose or a lactose-cellulose system as the principal filler, crospovidone or croscarmellose sodium as the primary disintegrant, colloidal silicon dioxide for flow and magnesium stearate at a controlled concentration. A dry process is attractive because it limits water exposure and reduces the risk of hydrolytic or process-related degradation.

What formulation problems must the excipient strategy solve?

How should poor olmesartan medoxomil solubility be addressed?

Olmesartan medoxomil is the key formulation constraint. It is a prodrug with limited aqueous solubility, so dissolution can become sensitive to particle size, crystal form, wetting, tablet hardness, lubricant distribution and disintegrant performance.

The commercial formulation strategy should prioritize:

1. Controlled active-particle size distribution.
2. Uniform distribution of the low-dose active across the blend.
3. Rapid tablet disintegration.
4. Adequate wetting without excessive surfactant-related instability.
5. Dissolution performance that remains consistent after scale-up.

Milling olmesartan medoxomil can improve dissolution but may increase electrostatic charging, agglomeration and blend segregation. A formulation using a premix or ordered mixture can improve content uniformity at low drug loads.

How should amlodipine and hydrochlorothiazide be protected?

Amlodipine besylate and hydrochlorothiazide are present at relatively low doses compared with the tablet mass. Their principal risks are content-uniformity failure and segregation rather than high total drug loading.

Amlodipine formulations should be protected from excessive light and moisture exposure where required by the drug substance and packaging system. Hydrochlorothiazide can create dissolution and uniformity challenges when combined with hydrophobic lubricants or over-compressed tablets.

A separate granulation for one or more active ingredients may improve uniformity but increases cost and process complexity. A direct-compression formulation is preferable when the active materials have compatible particle-size distributions and flow characteristics.

What excipients are used in the reference product?

The FDA-approved label identifies inactive ingredients for the marketed product, including conventional tablet fillers, binders, disintegrants, lubricants and film-coating materials. The exact composition can vary by strength and manufacturing site. The reference product should therefore be evaluated through the current FDA labeling record and, where necessary, the full regulatory product documentation rather than through secondary databases alone. [1]

For a generic developer, matching the qualitative and quantitative composition is not always required. An ANDA applicant may use a different excipient system if the product meets pharmaceutical equivalence, bioequivalence, quality and labeling requirements. The most valuable design-around space is usually in the filler-disintegrant system, coating composition, granulation route and particle-engineering approach.

How many patents protect Tribenzor and its generic competitors?

Tribenzor’s principal patent risk is historical rather than forward-looking. The product was protected through patents covering combinations of olmesartan medoxomil with amlodipine and, in some cases, hydrochlorothiazide, together with method-of-use and formulation subject matter.

A well-known patent associated with the olmesartan and amlodipine combination is U.S. Patent No. 6,878,703. Public patent records identify Daiichi Sankyo-related ownership and a term extending into the early 2020s, subject to patent-term adjustment and statutory calculation. [2] The relevant commercial question is whether any later-listed formulation or use patents remain enforceable against a proposed generic product.

What is the Orange Book status of Tribenzor?

The Orange Book is the controlling source for FDA-listed patents, pediatric exclusivity and patent certification requirements. The regulatory record for Tribenzor should be reviewed by NDA number, dosage form and listed patent use code. [3]

For an ANDA applicant, the relevant certification may include:

• Paragraph I, if no patent information is listed.
• Paragraph II, if the listed patent has expired.
• Paragraph III, if the applicant accepts a later launch date.
• Paragraph IV, if the applicant asserts that the patent is invalid, unenforceable or not infringed.

Because Tribenzor contains three established active ingredients and has been marketed for more than a decade, current entry analysis should focus on live Orange Book listings rather than the original approval-era patent portfolio.

When does olmesartan, amlodipine and hydrochlorothiazide lose exclusivity?

The product’s new-drug exclusivity period has expired. The relevant commercial barriers are patent term, regulatory review, ANDA approval timing and manufacturing readiness.

Exclusivity category	Status
FDA new-drug exclusivity	Expired
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	Must be checked against the current Orange Book record
Biosimilar exclusivity	Not applicable
Small-molecule patent exclusivity	Core historical protection extended into the early 2020s; current status depends on live listings
Generic pathway	ANDA under Section 505(j)

The practical generic launch window opened after expiration or successful challenge of relevant listed patents. A Paragraph IV filer may obtain 180-day exclusivity if it is eligible as a first applicant and satisfies the statutory requirements. [4]

Which companies are challenging Tribenzor?

The generic competitive field includes companies that develop combination antihypertensive tablets for U.S. ANDA approval and firms that market equivalent products outside the United States. Publicly reported ANDA applicants and approved products can change as FDA approvals, tentative approvals, transfers and marketing withdrawals occur.

A complete applicant-by-applicant list must be tied to the current FDA Orange Book and Drugs@FDA records. The commercially relevant point is that the product class has low technological entry barriers compared with complex injectables, modified-release products or biologics. Competition is therefore likely to include several suppliers once regulatory and supply-chain requirements are satisfied.

What Paragraph IV challenges and patent litigation affect the product?

Paragraph IV risk is concentrated in patents that claim:

• The triple active combination.
• Specific ratios of olmesartan medoxomil, amlodipine and hydrochlorothiazide.
• Pharmaceutical compositions with defined excipient systems.
• Methods for treating hypertension with the combination.
• Dissolution, particle-size or solid-state characteristics.

A generic sponsor can reduce litigation exposure through a product that avoids the listed method-of-use claims, uses a non-infringing formulation and files a section viii statement where permitted. Method-of-use carve-outs are especially relevant when the listed patent claims a patient subgroup or treatment regimen rather than the tablet itself.

The strongest litigation position generally arises from a claim directed to the composition or active combination itself. Excipients offer more design-around flexibility when the patent claims a specific formulation architecture rather than the active ingredients at broad functional levels.

What manufacturing and intellectual-property barriers remain?

Manufacturing barriers

The main technical barriers are:

• Maintaining dose uniformity across multiple low-dose actives.
• Preventing segregation during transfer and compression.
• Controlling olmesartan dissolution after scale-up.
• Avoiding over-lubrication.
• Managing tablet hardness and disintegration simultaneously.
• Preserving stability under high humidity.
• Producing multiple strengths without excessive tooling changes.

A common commercial solution is a platform formulation in which the excipient matrix remains substantially constant while active loading changes by strength. This can reduce validation cost and simplify inventory.

Intellectual-property barriers

Patent exposure can arise from more than the active combination. A developer should screen:

• Drug-substance particle engineering patents.
• Co-crystal, amorphous or solid-dispersion claims.
• Specific dissolution profiles.
• Bilayer or multilayer tablet claims.
• Taste-masking and coating claims.
• Manufacturing-process claims.
• Method-of-use patents covering resistant hypertension or treatment escalation.

A formulation that uses conventional excipients and direct compression generally has lower patent risk than one using a proprietary amorphous dispersion or novel delivery system.

What commercial opportunities exist for generic and branded-generic manufacturers?

U.S. generic opportunity

The U.S. opportunity is based on a high-volume hypertension market, chronic refills and the clinical convenience of replacing three separate tablets with one. The product can support:

• Standard ANDA entry.
• Authorized-generic supply.
• Retail and mail-order contracting.
• Medicaid and Medicare formulary supply.
• Private-label distribution.
• Institutional and government tenders.

Pricing pressure will be substantial because olmesartan, amlodipine and hydrochlorothiazide are individually generic and several dual combinations are available. The value proposition is adherence and regimen simplification, not active-ingredient novelty.

International opportunity

Outside the United States, opportunities are stronger in markets where:

• Fixed-dose combinations are favored by treatment guidelines.
• Hypertension diagnosis and treatment rates are increasing.
• Local manufacturers compete through branded generics.
• National tenders reward low-cost, stable supply.
• Patients prefer once-daily combination therapy.

Regional filings may require local bioequivalence studies, stability data under climatic zones III or IV, and country-specific excipient restrictions. Lactose, titanium dioxide, sodium lauryl sulfate and colorants can create formulation or labeling issues in certain markets.

Lifecycle opportunities

Potential lifecycle products include:

• Lower-dose initiation strengths.
• Amlodipine 10 mg or hydrochlorothiazide 25 mg optimization.
• Smaller tablets through higher-density excipients.
• Moisture-protective blister packaging.
• Scored or easier-to-swallow tablets where permitted.
• Hospital and institutional packs.
• Co-packaged titration kits.
• Fixed-dose combinations using alternative ARBs.

A new combination must establish a credible clinical or adherence advantage. A simple reformulation has limited pricing power unless it solves a measurable problem such as tablet size, dissolution variability or packaging stability.

How strong is the patent estate compared with competing antihypertensive combinations?

Product type	Patent strength	Generic entry difficulty	Commercial outlook
Olmesartan/amlodipine/HCTZ triple tablet	Low to moderate after core expiry	Moderate	Attractive for efficient manufacturers
Olmesartan/amlodipine dual tablet	Low to moderate	Low to moderate	Larger established generic market
Amlodipine/HCTZ combination	Low	Low	Price-sensitive
ARB/CCB/thiazide combinations with newer originators	Potentially higher	Moderate to high	Depends on remaining formulation patents
Long-acting injectable antihypertensive	Higher technical barrier	High	Different commercial model

The triple combination has a stronger formulation rationale than a simple me-too product because it addresses treatment escalation. Its patent estate, however, is weaker as a commercial barrier than estates protecting new chemical entities or complex delivery technologies.

What revenue exposure does the product create for originators and generic entrants?

Originator revenue exposure is limited by:

• Expired regulatory exclusivity.
• Availability of separate generic components.
• Therapeutic substitution.
• Reimbursement pressure.
• Multiple potential ANDA suppliers.

Generic revenue exposure is different. A supplier can lose meaningful value through:

• Failure to meet dissolution specifications.
• Recalls caused by content-uniformity failures.
• Supply interruptions.
• Inability to support multiple strengths.
• Contracting losses from price competition.
• Patent litigation delaying launch.

The best commercial position is usually held by a manufacturer with integrated API sourcing, validated low-cost compression, multiple packaging options and regulatory registrations in several jurisdictions.

What generic launch scenarios exist?

Scenario 1: Early non-infringing entry

A generic sponsor launches after determining that no enforceable listed patent blocks approval. This scenario provides the fastest market access but may trigger product-specific litigation if the originator asserts unlisted or non-Orange Book rights.

Scenario 2: Paragraph IV launch

The sponsor challenges a listed patent and launches at risk after litigation milestones permit entry. This can create substantial upside but exposes the company to damages and injunction risk.

Scenario 3: Settlement-based entry

The parties agree to a launch date before the asserted patent expiration. The commercial value depends on the negotiated date, authorized-generic terms and the number of competing entrants.

Scenario 4: Delayed international entry

A manufacturer launches first in markets where patent protection has expired or where the combination is not blocked by local rights. This can generate manufacturing scale before U.S. approval.

Key Takeaways

• Tribenzor is a mature small-molecule fixed-dose combination of olmesartan medoxomil, amlodipine and hydrochlorothiazide.
• The formulation’s principal technical challenge is dissolution and uniformity of poorly soluble olmesartan medoxomil in a multi-active tablet.
• A cellulose-lactose or cellulose-mannitol filler system with a robust superdisintegrant and controlled lubrication is commercially practical.
• Direct compression or dry granulation can reduce moisture exposure and manufacturing cost.
• FDA new-drug exclusivity has expired, and biosimilar competition does not apply.
• Current entry analysis must rely on the live Orange Book record, patent use codes and litigation status.
• The strongest commercial opportunities are generic ANDA entry, private-label supply, international branded generics and manufacturing-platform reuse.
• Formulation patents can be designed around more readily than broad composition patents.
• Revenue potential depends on scale, supply reliability, multi-strength coverage and contracting discipline rather than premium pricing.

FAQs

Is olmesartan medoxomil compatible with direct compression?

It can be, provided particle size, flow, segregation, lubrication and dissolution are controlled. Dry granulation may be preferable when direct compression produces unacceptable uniformity or tabletability.

Which excipient is most important for improving olmesartan dissolution?

No single excipient is universally optimal. A superdisintegrant combined with improved wetting, controlled particle size and low over-lubrication is generally more reliable than a high surfactant concentration alone.

Can a generic manufacturer use different excipients from Tribenzor?

Yes. A generic product may use a different inactive-ingredient system if it satisfies FDA pharmaceutical-equivalence, bioequivalence, quality, safety and labeling requirements.

Does this combination require a biosimilar application?

No. The product contains small-molecule active ingredients and is approved through the NDA or ANDA framework, not the biologics license application or biosimilar pathway.

Is a new olmesartan, amlodipine and hydrochlorothiazide formulation commercially patentable?

Potentially, but patentability depends on novelty, non-obviousness and adequate disclosure. Stronger opportunities may involve a non-obvious dissolution profile, stable solid form, manufacturing process or clinically meaningful dosage design rather than routine excipient substitution.

References

1. U.S. Food and Drug Administration. (2010). Tribenzor: Prescribing information, NDA 202895. FDA Drugs@FDA.

2. U.S. Patent and Trademark Office. (2005). U.S. Patent No. 6,878,703: Pharmaceutical composition comprising an angiotensin II antagonist and a calcium channel blocker. Washington, DC: U.S. Department of Commerce.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application approvals and 180-day exclusivity. FDA.